Market Place
Sourcing Support
Lysogene Announces the Extension of Deadline for the Submission of Offers
16 Feb 2023 //
BUSINESSWIRE
Lysogene: Conversion of Safeguard Proceedings Into Reorganization Proceedings
25 Jan 2023 //
BUSINESSWIRE
Lysogene: Launch of a Process to Find Buyers or Investors and Request
06 Jan 2023 //
BUSINESSWIRE
A former Sarepta partner asks French courts to oversee restructuring
08 Dec 2022 //
ENDPTS
Lysogene looks for saving grace after trial flop
07 Dec 2022 //
FIERCEBIOTECH
Lysogene Provides Updates Results from Phase 2/3 AAVance Gene Therapy Study
29 Nov 2022 //
BUSINESSWIRE
Lysogene`s lead gene therapy fails phase 2/3 trial with cash low
19 Nov 2022 //
FIERCEPHARMA
Lysogene Provides Updates & Topline Results from Ph 2/3 AAVance Gene Therapy Cl
18 Nov 2022 //
BUSINESSWIRE
Lysogene to Provide Updates and Topline Results Ph 2/3 AAVance Gene Therapy
18 Nov 2022 //
BUSINESSWIRE
Lysogene Provides Clinical Update on AAVance PII/III Trial with LYS-SAF302
18 May 2022 //
BUSINESSWIRE
Lysogene Publishes Positive Preliminary Preclinical Results in the Treatment
21 Apr 2022 //
LYSOGENE
Lysogene and Yeda enter gene therapy licencing deal
13 Apr 2022 //
PHARMACEUTICAL-TECHNOLOGY
Lysogene Partners with Yeda for Neuronopathic Gaucher Disease and PD
12 Apr 2022 //
BUSINESSWIRE
Lysogene Provides Update on Phase 2/3 Trial with Gene Therapy LYS-SAF302
24 Feb 2022 //
BUSINESSWIRE
Lysogene: Positive Biomarker Data With LYS-SAF302, Safety Data With LYS-GM101
11 Feb 2022 //
BUSINESSWIRE
Lysogene Provides Medical Update
07 Feb 2022 //
BUSINESSWIRE
Lysogene Reports its Cash Position as of 31 December 2021
27 Jan 2022 //
PRESS RELEASE
Lysogene Announces Termination of License Agreement With Sarepta for LYS-SAF302
12 Jan 2022 //
BIOSPACE
Half-Year report on the liquidity contract signed by Lysogene with Kepler Cheuvreux
05 Jan 2022 //
PRESS RELEASE
UK MHRA awards Innovation Passport to Lysogene’s LYS-GM101 in GM1 gangliosidosis
21 Dec 2021 //
PHARMABIZ
Lysogene Secures a €4.3 Million Non-dilutive Financing From Bpifrance to Support
26 Nov 2021 //
BUSINESSWIRE
Lysogene Announces a Presentation of its LYS-GM101 Program at the ESGCT 2021
18 Oct 2021 //
BUSINESSWIRE
Lysogene Announces Gene Therapy Clinical Trial with LYS-GM101
30 Aug 2021 //
BUSINESSWIRE
US FDA grants fast track status to Lysogene’s LYS-GM101 gene therapy
12 Jul 2021 //
PHARMABIZ
Lysogene Announces FDA Fast Track Designation for LYS-GM101 Gene Therapy
07 Jul 2021 //
BUSINESSWIRE
Lysogene signs exclusive worldwide license agreement with SATT Conectus
11 Jun 2021 //
BUSINESSWIRE
Lysogene signs exclusive worldwide license agreement with SATT Conectus
11 Jun 2021 //
BUSINESSWIRE
Lysogene Enters into an Exclusive Worldwide License Agreement with SATT Conectus
10 Jun 2021 //
BUSINESSWIRE
Lysogene Announces First Patient Dosed with LYS-GM101
09 Jun 2021 //
BUSINESSWIRE
Lysogene Reports LYS-SAF302 Biomarker Data Presented at the WORLDSymposium™ 2021
15 Feb 2021 //
BIOSPACE
Lysogene Receives FDA Clearance of Investigational New Drug Application
11 Feb 2021 //
BUSINESSWIRE
Lysogene Receives FDA Clearance of Investigational New Drug Application
11 Feb 2021 //
BUSINESSWIRE
Lysogene Receives MHRA and Research Ethics Committee Approvals Gene Therapy
11 Jan 2021 //
BUSINESSWIRE
Lysogene Receives MHRA and Research Ethics Committee Approvals Gene Therapy
11 Jan 2021 //
BIOSPACE
Lysogene Reports Positive Biomarker Data With LYS-SAF302
28 Dec 2020 //
COM/INDEX
Lysogene Reports Positive Biomarker Data With LYS-SAF302
28 Dec 2020 //
COM/INDEX
Cause of Death Unknown in Child Participating in LYS-SAF302 Gene Therapy Trial
12 Nov 2020 //
SANFILIPPONEWS
Five-year-old girl that was part of Lysogene’s gene therapy clinical trial dies
17 Oct 2020 //
PHARMAFILE
Lysogene Provides Update on the AAVance Clinical Trial Evaluating LYS-SAF302
15 Oct 2020 //
APNEWS
Patient death in pivotal gene therapy trial rattles Sarepta partner already hold
15 Oct 2020 //
ENDPTS
Lysogene Reports First Half 2020 Financial Results & Provides Operational Update
24 Sep 2020 //
BUSINESSWIRE
Lysogene, Weizmann Institute Team Up on Gene Therapy for Neuronopathic Gaucher
06 Jul 2020 //
GAUCHERDISEASENEWS
Lysogene enters research pact with Weizmann Institute Science AAV gene therapy
02 Jul 2020 //
PHARMABIZ
Lysogene announces important updates 2/3 trial with LYS-SAF302 in MPS IIIA
04 Jun 2020 //
PIPELINEREVIEW
